keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/29331342/development-of-a-prognostic-score-to-predict-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#1
Carlo Spreafico, Carlo Sposito, Marta Vaiani, Tommaso Cascella, Sherrie Bhoori, Carlo Morosi, Rodolfo Lanocita, Raffaele Romito, Carlo Chiesa, Marco Maccauro, Alfonso Marchianò, Vincenzo Mazzaferro
BACKGROUND & AIMS: Yttrium-90 trans-arterial radioembolization (TARE) has shown promising efficacy in the treatment of patients with hepatocellular carcinoma (HCC) associated with tumoral portal vein thrombosis (PVTT). Aim of this study is to identify prognostic factors for survival in patients with HCC and PVTT undergoing TARE, and build a prognostic classification for these patients. METHODS: This is a single Center retrospective study conducted over 6 years (2010-2015), on consecutive patients undergoing TARE...
January 10, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29329568/prospective-longitudinal-quality-of-life-and-survival-outcomes-in-patients-with-advanced-infiltrative-hepatocellular-carcinoma-and-portal-vein-thrombosis-treated-with-yttrium-90-radioembolization
#2
Minzhi Xing, Nima Kokabi, Juan C Camacho, Hyun S Kim
BACKGROUND: To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) patients with concurrent portal vein thrombosis (PVT). METHODS: Consecutive patients with unresectable infiltrative HCC and PVT were recruited. The Short-Form 36 (SF-36) questionnaire was used to assess HRQOL for consecutive patients treated with glass-based Y90 based on a prospective phase II trial...
January 12, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29327692/a-pet-reconstruction-formulation-that-enforces-non-negativity-in-projection-space-for-bias-reduction-in-y-90-imaging
#3
Hongki Lim, Yuni K Dewaraja, Jeffrey A Fessler
Most existing PET image reconstruction methods impose a nonnegativity constraint in the image domain that is natural physically, but can lead to biased reconstructions. This bias is particularly problematic for Y-90 PET because of the low probability positron production and high random coincidence fraction. This paper investigates a new PET reconstruction formulation that enforces nonnegativity of the projections instead of the voxel values. This formulation allows some negative voxel values, thereby potentially reducing bias...
January 12, 2018: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/29325784/kinetic-analysis-of-contralateral-liver-hypertrophy-after-radioembolization-of-primary-and-metastatic-liver-tumors
#4
Sonia T Orcutt, Yazan Abuodeh, Arash Naghavi, Jessica Frakes, Sarah Hoffe, Bela Kis, Daniel A Anaya
BACKGROUND: Radioembolization induces liver hypertrophy, although the extent and rate of hypertrophy are unknown. Our goal was to examine the kinetics of contralateral liver hypertrophy after transarterial radioembolization. METHODS: A retrospective study (2010-2014) of treatment-naïve patients with primary/secondary liver malignancies undergoing right lobe radioembolization was performed. Computed tomography volumetry was performed before and 1, 3, and 6 months after radioembolization...
January 8, 2018: Surgery
https://www.readbyqxmd.com/read/29299369/pretreatment-albumin-may-aid-in-patient-selection-for-intrahepatic-y-90-microsphere-transarterial-radioembolization-tare-for-malignancies-of-the-liver
#5
Kelly P Orwat, Thomas H Beckham, Samuel Lewis Cooper, Michael S Ashenafi, Michael Bret Anderson, Marcelo Guimaraes, Ricardo Yamada, David T Marshall
Background: Hepatic malignancies are common including primary malignancies and metastases. Transarterial radioembolization (TARE) is an important treatment option. We reviewed safety and efficacy of (TARE) in our patients to identify factors that may impact treatment outcomes in a heterogeneous population. Methods: All patients that received TARE at the Medical University of South Carolina from March 2006 through May of 2014 were included. Kaplan-Meier estimates on overall survival (OS) from date of first procedure are reported...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29251517/yttrium-90-resin-microspheres-and-their-use-in-the-treatment-of-intrahepatic-cholangiocarcinoma
#6
Luca Filippi, Orazio Schillaci, Roberto Cianni, Oreste Bagni
Intrahepatic cholangiocarcinoma (ICC) is a severe and rapidly progressive hepatic tumor. Surgery is often impracticable due to locally advanced presentation. On the other hand, chemotherapy has demonstrated only limited effectiveness. For these reasons, liver-directed therapies have been successfully applied for treating ICC. In particular, radioembolization with Yttrium-90 (90Y)-labeled spheres has been reported to be a promising therapeutic approach for this neoplasia. Two commercial forms of 90Y-labeled spheres are available: glass (TheraSphere®) and resin (SIR-Spheres®) microspheres...
December 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/29249594/anatomic-versus-metabolic-tumor-response-assessment-after-radioembolization-treatment
#7
Jennifer M J Jongen, Charlotte E N M Rosenbaum, Manon N G J A Braat, Maurice A A J van den Bosch, Daniel Y Sze, Onno Kranenburg, Inne H M Borel Rinkes, Marnix G E H Lam, Andor F van den Hoven
PURPOSE: To assess applicability of metabolic tumor response assessment on 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) after radioembolization (RE) in patients with colorectal liver metastases (CRLM) by comparison with one-dimensional size-based response assessment on MR imaging. MATERIALS AND METHODS: This prospective cohort study comprised 38 patients with CRLM undergoing RE. MR imaging and 18F-FDG PET/CT imaging were performed at baseline, 1 month (n = 38), and 3 months (n = 21)...
December 14, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29231047/cost-effectiveness-analysis-of-treatments-involving-radioembolization-in-intermediate-stage-hepatocellular-carcinoma
#8
Carla Rognoni, Oriana Ciani, Silvia Sommariva, Rosanna Tarricone
AIM: We evaluated two treatment sequences, transarterial radioembolization followed by transarterial chemoembolization and possibly sorafenib (=TTS) versus transarterial radioembolization followed by sorafenib alone (=TS), to identify the most cost-effective pathway to treat intermediate-stage hepatocellular carcinoma from the Italian healthcare system perspective. MATERIALS & METHODS: A Markov model was developed to project costs and health outcomes for TTS and TS over a lifetime horizon...
December 12, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29230556/liver-directed-therapy-for-hepatocellular-carcinoma
#9
Kazim H Narsinh, David P Duncan, Isabel G Newton, Jeet Minocha, Steven C Rose
Liver-directed therapy is a critical component of treatment strategies for hepatocellular carcinoma. These therapies included percutaneous image-guided ablation, transarterial chemoembolization, and transarterial radioembolization, and are administered by interventional radiologists. Depending on the stage of disease, a particular treatment modality, or a combination thereof, is expected to be most efficacious in achieving the goals of treatment for a particular patient. This article seeks to review the various liver-directed treatment modalities for treatment of hepatocellular carcinoma, with attention to their efficacy and patient selection criteria...
December 11, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/29230127/intraarterial-liver-directed-therapies-the-role-of-interventional-oncology
#10
REVIEW
Jenson Ma, Juan Martin Gimenez, Tyler Sandow, Daniel Devun, David Kirsch, Paul Gulotta, Patrick Gilbert, Dennis Kay
Background: Since the early 1990s, the minimally invasive image-guided therapies used in interventional oncology to treat hepatocellular carcinoma have continued to evolve. Additionally, the range of applications has been expanded to the treatment of hepatic metastases from colorectal cancer, neuroendocrine tumors, cholangiocarcinoma, breast cancer, melanoma, and sarcoma. Methods: We searched the literature to identify publications from 1990 to the present on various image-guided intraarterial therapies and their efficacy, as well as their role in the management of primary and secondary liver malignancies...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29225073/corrigendum-to-131i-labeled-chitosan-hydrogels-for-radioembolization-a-preclinical-study-in-small-animals-nucl-med-biol-52-2017-16-23
#11
Hyosook Hwang, Kwang Il Kim, JeongIl Kwon, Byoung Soo Kim, Hwan-Seok Jeong, Su Jin Jang, Phil-Sun Oh, Ho Sung Park, Seok Tae Lim, Myung-Hee Sohn, Hwan-Jeong Jeong
No abstract text is available yet for this article.
December 7, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29217739/y90-radioembolization-for-locally-advanced-hepatocellular-carcinoma-with-portal-vein-thrombosis-long-term-outcomes-in-a-185-patient-cohort
#12
Nadine Abouchaleh, Ahmed Gabr, Rehan Ali, Ali Al Asadi, Ronald A Mora, Joseph Ralph Kallini, Karen Marshall, Laura Kulik, Samdeep Mouli, Daniela P Ladner, Michael Abecassis, Juan C Caicedo, Ahsun Riaz, Robert J Lewandoski, Riad Salem
Purpose: To report survival outcomes for advanced stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with radioembolization (Y90). Methods: With IRB approval we searched our prospectively acquired database for patients treated with Y90 between 2003 and 2017. Inclusion criteria were patients who had advanced stage HCC with tumor PVT. In order to minimize confounding effect, patients with metastases were excluded. Clinical and laboratory data were collected at baseline and 1 month post-Y90...
December 7, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29206288/absorbed-dose-kernel-and-self-shielding-calculations-for-a-novel-radiopaque-glass-microsphere-for-transarterial-radioembolization
#13
Cody Church, George Mawko, John Paul Archambault, Robert Lewandowski, David Liu, Sharon Kehoe, Daniel Boyd, Robert Abraham, Alasdair Syme
PURPOSE: Radiopaque microspheres may provide intraprocedural and postprocedural feedback during transarterial radioembolization (TARE). Furthermore, the potential to use higher-resolution x-ray imaging techniques as opposed to nuclear medicine imaging suggests that significant improvements in the accuracy and precision of radiation dosimetry calculations could be realized for this type of therapy. This study investigates the absorbed dose kernel for novel radiopaque microspheres including contributions of both short and long-lived contaminant radionuclides while concurrently quantifying the self-shielding of the glass network...
December 5, 2017: Medical Physics
https://www.readbyqxmd.com/read/29194711/institutional-decision-to-adopt-y90-as-primary-treatment-for-hcc-informed-by-a-1-000-patient-15-year-experience
#14
Riad Salem, Ahmed Gabr, Ahsun Riaz, Ronald Mora, Rehan Ali, Michael Abecassis, Ryan Hickey, Laura Kulik, Daniel Ganger, Steven Flamm, Rohi Atassi, Bassel Atassi, Kent Sato, Al B Benson, Mary F Mulcahy, Nadine Abouchaleh, Ali Al Asadi, Kush Desai, Bartley Thornburg, Michael Vouche, Ali Habib, Juan Caicedo, Frank H Miller, Vahid Yaghmai, Joseph R Kallini, Samdeep Mouli, Robert J Lewandowski
Y90 transarterial radioembolization (TARE) is a transarterial locoregional therapy (LRT) for hepatocellular carcinoma (HCC). In this study, we present overall survival outcomes (OS) in a 1000-patient cohort acquired over a 15-year period. Between December 1, 2003 and March 31, 2017, 1000 patients with HCC were treated with TARE as part of a prospective cohort study. A comprehensive review of toxicity and survival outcomes was performed. Outcomes were stratified by baseline Child-Pugh (CP) class, United Network for Organ Sharing (UNOS) and Barcelona Clinic Liver Cancer (BCLC) staging systems...
December 1, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29185067/phantom-validation-of-quantitative-y-90-pet-ct-based-dosimetry-in-liver-radioembolization
#15
Marco D'Arienzo, Maria Pimpinella, Marco Capogni, Vanessa De Coste, Luca Filippi, Emiliano Spezi, Nick Patterson, Francesca Mariotti, Paolo Ferrari, Paola Chiaramida, Michael Tapner, Alexander Fischer, Timo Paulus, Roberto Pani, Giuseppe Iaccarino, Marco D'Andrea, Lidia Strigari, Oreste Bagni
BACKGROUND: PET/CT has recently been shown to be a viable alternative to traditional post-infusion imaging methods providing good quality images of 90Y-laden microspheres after selective internal radiation therapy (SIRT). In the present paper, first we assessed the quantitative accuracy of 90Y-PET using an anthropomorphic phantom provided with lungs, liver, spine, and a cylindrical homemade lesion located into the hepatic compartment. Then, we explored the accuracy of different computational approaches on dose calculation, including (I) direct Monte Carlo radiation transport using Raydose, (II) Kernel convolution using Philips Stratos, (III) local deposition algorithm, (IV) Monte Carlo technique (MCNP) considering a uniform activity distribution, and (V) MIRD (Medical Internal Radiation Dose) analytical approach...
November 28, 2017: EJNMMI Research
https://www.readbyqxmd.com/read/29177870/dosimetric-parameters-predicting-contralateral-liver-hypertrophy-after-unilobar-radioembolization-of-hepatocellular-carcinoma
#16
Xavier Palard, Julien Edeline, Yan Rolland, Samuel Le Sourd, Marc Pracht, Sophie Laffont, Laurence Lenoir, Karim Boudjema, Thomas Ugen, Vanessa Brun, Habiba Mesbah, Laure-Anne Haumont, Pascal Loyer, Etienne Garin
PURPOSE: This study aimed at identifying prior therapy dosimetric parameters using 99mTc-labeled macro-aggregates of albumin (MAA) that are associated with contralateral hepatic hypertrophy occurring after unilobar radioembolization of hepatocellular carcinoma (HCC) performed with 90Y-loaded glass microspheres. METHODS: The dosimetry data of 73 HCC patients were collected prior to the treatment with 90Y-loaded microspheres for unilateral disease. The injected liver dose (ILD), the tumor dose (TD) and healthy injected liver dose (HILD) were calculated based on MAA quantification...
November 25, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29172243/characterization-of-90y-spect-ct-self-calibration-approaches-on-the-quantification-of-voxel-level-absorbed-doses-following-90y-microsphere-selective-internal-radiation-therapy
#17
Anjali Balagopal, Cheenu Kappadath
PURPOSE: 90Y-microsphere selective internal radiation therapy (90Y-SIRT or 90Y-radioembolization) is used in the management of unresectable liver tumors. 90Y-SIRT presents a unique situation where the total 90Y activity inside the liver can be determined with high accuracy (>95%). 90Y bremsstrahlung single-photon emission computed tomography (SPECT)/computed tomography (CT) can be self-calibrated to provide quantitative images that facilitate voxel-level absorbed dose calculations...
November 24, 2017: Medical Physics
https://www.readbyqxmd.com/read/29169782/radiation-segmentectomy-versus-selective-chemoembolization-in-the-treatment-of-early-stage-hepatocellular-carcinoma
#18
Derek M Biederman, Joseph J Titano, Ricki A Korff, Aaron M Fischman, Rahul S Patel, Francis S Nowakowski, Robert A Lookstein, Edward Kim
PURPOSE: To compare outcomes of radiation segmentectomy (RS) and segmental transarterial chemoembolization in treatment of unresectable, solitary hepatocellular carcinoma (HCC) ≤ 3 cm. MATERIALS AND METHODS: From January 2012 to January 2016, 534 and 877 patients were treated with radioembolization and transarterial chemoembolization, respectively. A cohort of 112 (radiation segmentectomy [RS], 55; chemoembolization, 57) locoregional therapy-naïve patients with solitary HCC ≤ 3 cm without vascular invasion or metastasis was retrospectively identified and stratified according to baseline patient demographics, tumor characteristics, and laboratory values...
January 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29168007/can-dual-energy-ct-replace-perfusion-ct-for-the-functional-evaluation-of-advanced-hepatocellular-carcinoma
#19
Sébastien Mulé, Frédéric Pigneur, Ronan Quelever, Arthur Tenenhaus, Laurence Baranes, Philippe Richard, Vania Tacher, Edouard Herin, Hugo Pasquier, Maxime Ronot, Alain Rahmouni, Valérie Vilgrain, Alain Luciani
OBJECTIVES: To determine the degree of relationship between iodine concentrations derived from dual-energy CT (DECT) and perfusion CT parameters in patients with advanced HCC under treatment. METHODS: In this single-centre IRB approved study, 16 patients with advanced HCC treated with sorafenib or radioembolization who underwent concurrent dynamic perfusion CT and multiphase DECT using a single source, fast kV switching DECT scanner were included. Written informed consent was obtained for all patients...
November 22, 2017: European Radiology
https://www.readbyqxmd.com/read/29167951/radioembolization-versus-bland-embolization-for-hepatic-metastases-from-small-intestinal-neuroendocrine-tumors-short-term-results-of-a-randomized-clinical-trial
#20
Anna-Karin Elf, Mats Andersson, Olof Henrikson, Oscar Jalnefjord, Maria Ljungberg, Johanna Svensson, Bo Wängberg, Viktor Johanson
BACKGROUND: Radioembolization (RE) with intra-arterial administration of (90)Y microspheres is a promising technique for the treatment of liver metastases from small intestinal neuroendocrine tumors (SI-NET) not amenable to surgery or local ablation. However, studies comparing RE to other loco-regional therapies are lacking. The aim of this randomized study was to compare the therapeutic response and safety after RE and bland hepatic arterial embolization (HAE), and to investigate early therapy-induced changes with diffusion-weighted MRI (DWI-MRI)...
November 22, 2017: World Journal of Surgery
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"